Anju Parthan - Concepedia

Author

Anju Parthan

Optum (United States)ORCID

Also Known As

A Parthan, A. Parthan, Anju Parthan, Nowak, Richard J.

Publications

597

Citations

H-Index

Concepts

All Affiliations

Optum (United States)HealthInsight Amgen (United States)Harvard University Marshall B. Ketchum University

About

Anju Parthan is an author at Optum (United States) specializing in medicine, health policy, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	234
2	Public Health	4	4	118
3	Health Sciences	1	1	59
4	Diabetes	1	1	14
5	Epidemiology	1	1	12

Anju Parthan

Publications

411

Citations

H-Index

Page 1

	Year	Citations
Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US Anju Parthan, Morgan Kruse, Nicole Yurgin, Applied Health Economics and Health Policy Bone DiseaseBone HealthHealth EconomicsPostmenopausal OsteoporosisOutcomes Research	2013	78
Comparative Cost-Effectiveness of Stereotactic Body Radiation Therapy Versus Intensity-Modulated and Proton Radiation Therapy for Localized Prostate Cancer Anju Parthan, Narin Pruttivarasin, D.R.A. Davies, Frontiers in Oncology	2012	68
Chronic low back pain: epidemiology, economic burden and patient-reported outcomes in the USA Anju Parthan, Christopher J. Evans, Kim Le Expert Review of Pharmacoeconomics & Outcomes Research Patient-reported OutcomesPain MedicinePain SyndromeMuscle RelaxantsChronic Musculoskeletal Condition	2006	59
Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective Stuart L. Silverman, Irene Agodoa, Morgan Kruse, Journal of Osteoporosis Cost-effectiveness AnalysisPharmacotherapyOrthopaedic SurgeryOsteoporosisBone Disease	2015	33
Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma Kelly Fust, Xiaoyan Li, Michael Maschio, PharmacoEconomics	2016	33
Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective Anju Parthan, M. Kruse, Irene Agodoa, Bone Bone DiseaseHealth PolicyOsteopathyMedicineSwedish Payer Perspective	2013	28
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck Anju Parthan, Marshall R. Posner, Caroline Brammer, Head & Neck	2009	25
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States Myrlene Sanon, Douglas C.A. Taylor, Anju Parthan, Journal of Medical Economics	2012	20
A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture Claire E O’Hanlon, Anju Parthan, Morgan Kruse, Clinical Therapeutics	2017	20
Strategies to improve adherence with medications in chronic, ‘silent’ diseases representing high cardiovascular risk Anju Parthan, G Vincze, Donald E. Morisky, Expert Review of Pharmacoeconomics & Outcomes Research Disease ManagementHypertensionHigh Cardiovascular RiskMultiple Adherence MeasurementsPharmacotherapy	2006	14

Page 1